• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of bmccancBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Cancer
BMC Cancer. 2005; 5: 101.
Published online Aug 11, 2005. doi:  10.1186/1471-2407-5-101
PMCID: PMC1199587

No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin

Abstract

Background

The mechanisms of chemoresistance in ovarian cancer patients remain largely to be elucidated. Paclitaxel/cisplatin combination is the standard chemotherapeutic treatment for this disease, although some patients do not respond to therapy. Our goals were to investigate whether TUBB mutations and mismatch repair defects underlie paclitaxel and cisplatin resistance.

Methods

Thirty-four patients with primary ovarian carcinomas (26 serous and eight clear cell carcinomas) treated with paclitaxel/cisplatin were analysed. TUBB exon 4 was analysed by nested PCR after a first round PCR using intronic primers. Microsatellite analysis was performed with the quasimonomorphic markers BAT 26 and BAT 34.

Results

Twenty-two of the 34 ovarian cancers (64.7%) presented residual tumour after surgery, seven of which (7/22; 31.8%) were shown to be chemoresistant (five serous and two clear cell tumours). Sequence analysis did not find any mutation in TUBB exon 4. Microsatellite instability was not detected in any of the ovarian carcinomas.

Conclusion

We conclude that TUBB exon 4 mutations and mismatch repair defects do not play a significant role in paclitaxel/cisplatin resistance.

Background

Ovarian cancer is the fourth most common cancer in women [1]. The standard treatment for ovarian cancer is cytoreductive surgery followed by combination systemic chemotherapy [2]. Since the middle 90's, the combination paclitaxel/cisplatin became the standard chemotherapeutic treatment for poor prognosis ovarian cancer [3]. Nevertheless, some patients are resistant to this chemotherapeutic treatment, making it important to clarify the underlying mechanisms of resistance [4].

Paclitaxel binds to microtubules and causes kinetic suppression (stabilisation) of microtubule dynamics, promoting their polymerisation and cell cycle arrest in mitosis (antimitotic activity), which probably leads to apoptosis [5,6]. Microtubules are composed of a dimeric protein, tubulin, with alpha (α) and beta (β) tubulin heterodimers in dynamic equilibrium. The β-tubulin gene (TUBB), mapped to 6p21.3 [7], is composed of four exons and encodes a 445-aminoacid protein with GTPase function to which paclitaxel preferentially binds [8]. Cisplatin is activated intracellularly and establishes inter- and intra-strand DNA adducts that block replication and translation. The fate of cells after cisplatin exposure depends both on the extent of DNA damage and the cellular response to it, and apoptosis can be induced as a consequence [5,9]. Although the specific mechanism that triggers apoptosis is not totally clear, some evidence suggests that this process can be mediated by the DNA mismatch repair system (MMR) [5,9].

Drug resistance is considered a multifactorial process, but the detailed mechanisms are still unknown. Recently, point mutations in the β-tubulin gene, predominantly in exon 4, were associated with resistance to paclitaxel [10-12]. Resistance to cisplatin was linked with anomalies in the DNA MMR system resulting in microsatellite instability (MSI) [13-16]. In order to evaluate the relevance of these mechanisms to ovarian cancer chemoresistance, we screened TUBB exon 4 for mutations and performed MSI analysis in 34 ovarian carcinomas treated with paclitaxel/cisplatin and evaluated patients' response to chemotherapy.

Methods

Patient data

Thirty-four primary ovarian carcinoma patients, of serous (26 cases) or clear cell (eight cases) histological types (invasive or borderline), consecutively admitted at the Portuguese Oncology Institute – Porto and treated with the adjuvant chemotherapy scheme paclitaxel/cisplatin, were analysed. Patients previously treated with other chemotherapeutic regimens or radiotherapy were excluded from the study.

Evaluation of treatment responses was done by an oncologist using computerized tomography or magnetic resonance and CA125 quantification, according to international guidelines [17]. Investigators performing laboratory analysis were not aware of chemotherapy response or resistance until the study was completed.

DNA extraction

Genomic DNA was extracted from chemo-naïve, paraffin embedded tumours, after dissection. Tissue blocks were sectioned, mounted on glass slides, deparaffinised, and stained with haematoxylin and eosin. Tumour areas were identified under the microscope on each slide and marked. Areas with at least 70% of cancer cells were identified on tissue sections. Selected paraffin blocks were sectioned (5μm sections) and mounted in microscope slides. Marked tumour areas were selected with a sterile razor blade. Three sections of tissue were incubated in a solution of 10 mM Tris-HCl buffer (pH 8.0), 2.5 mM MgCl2, 50 mM KCl, 0.5% (p/v) Tween 20, and 1 mg/mL proteinase K for 48 hours at 55°C.

TUBB exon 4 sequencing

For polymerase chain reaction (PCR) assays, different sets of oligonucleotides were designed to amplify specific regions of TUBB exon 4 that code for the GTP and paclitaxel binding sites. To assure that the amplicon was not a pseudogene, the following intronic primer set was used in the first round PCR: 5'AAG-GAG-ATA-CAT-CCG-AGG-GAA-TT3' and 5'AAG-GTA-TTC-ATG-ATG-CGA3'. After checking for first round PCR product in an agarose gel, a 1:10 dilution was used for nested PCRs with the following primers: set 1, 5'AGA-GAG-CTG-TGA-CTG-CCT-G3' and 5'AAG-GTA-TTC-ATG-ATG-CGA3'; set 2, 5'GCT-CTG-GAA-TGG-GCA-CTC3' and 5'CCG-TAG-GTT-GGT-TGT-GGT-CA3'; set 3, 5'CGG-GGA-TCT-GAA-CCA-CCT-T3' and 5'GAG-TGT-CAC-GGC-CTG-GAG-T3'. The PCR products were separated by electrophoresis in agarose gels stained with ethidium bromide and analysed in a transiluminator. All DNA samples were analysed in an automatic DNA sequencer ABI PRISM 310™ Genetic Analyser. The sequences were compared with the genomic sequence GenBank AF070600.

MSI evaluation

For microsatellite analysis, tumour DNA was amplified with primers for two quasimonomorphic markers BAT 26 (5'GAG-TGT-CAC-GGC-CTG-GAG-T3'; 5'AAC-CAT-TCA-ACA-TTT-TTA-ACC-C3') and BAT 34 (5'ACC-CTG-GAG-GAT-TTC-ATC-TC3'; 5'AAC-AAA-GCG-AGA-CCC-AGT-CT3') [18-20]. Fragments were analysed in an ABI PRISM 310™ Genetic Analyser.

Results

Twenty-two of the 34 ovarian cancers (64.7%) presented residual tumour after surgery, seven of which (7/22; 31.8%) were shown to be chemoresistant (five serous and two clear cell tumours) (Table (Table11).

Table 1
Clinical, pathological and genetic data of 34 ovarian cancer patients.

Amplicons of 700 bp were observed for all cases after amplification with the intronic primers (data not shown). Nested PCR with primer sets 1–3 specific for TUBB exon 4 resulted in amplicons with 129, 254, and 201 bp, respectively (Figure (Figure1).1). Sequencing analysis of all 34 cases showed no TUBB exon 4 mutations (Figure (Figure22).

Figure 1
Nested PCR products (in duplicate) obtained with the three primer sets specific for TUBB exon 4 in an ovarian carcinoma (from right to left, lane 1: 100 bp step ladder; lanes 2 and 3: 129 bp amplicon – set 1 primers; lanes 4 and 5: 254 bp amplicon ...
Figure 2
Electrophorogram of part of TUBB exon 4 without any sequence variation in an ovarian carcinoma.

Microsatellite analysis with markers BAT 26 and BAT 34 (Figure (Figure3)3) showed the normal pattern in all cases, so no evidence for microsatellite instability was detected in this series.

Figure 3
Electrophorograms of BAT 26 (A) and BAT 34 (B) markers in an ovarian carcinoma, showing the same pattern found in normal control DNA.

Discussion

Tumour resistance to chemotherapy or disease relapses resistant to further treatment after an initial response are common events in current cytotoxic cancer treatment regimens [5]. With regard to ovarian cancer chemotherapy, the current major challenge is to understand why histologically similar tumours behave so differently when treated with the same chemotherapeutic regimen. The action of a drug potentially depends on several mechanisms, namely, metabolisation, access into the tumour microenvironment, intracellular uptake, interaction with the target, and subsequent signalling events [5]. It is therefore important to study the different molecular mechanisms that can be involved in chemotherapy resistance.

The rationale for studying the relationship between TUBB gene mutations with paclitaxel resistance came from the studies of Giannakakou et al and Gonzalez-Garay et al [10,11], who found TUBB mutations in ovarian cancer cell lines and in hamster cells, respectively. Subsequently, Monzó et al [12] reported TUBB mutations in 16 out of 36 (44.4%) paclitaxel resistant tumour samples from patients with advanced non-small cell lung cancer and proposed that TUBB mutations could represent a possible mechanism of paclitaxel resistance in that tumour type.

However, our findings in the present study argue against a significant role of TUBB gene mutations in paclitaxel resistance in ovarian cancer. In keeping with our results, Sale et al [22] and Lamendola et al [23] did not detect TUBB gene mutations in ovarian cancer samples. Similar findings have recently been obtained for several other tumour types, namely, lung [24], breast [25,26], and gastric cancer [27]. Taken together, our and several other investigations concur that TUBB exon 4 mutations are not an important mechanism underlying paclitaxel resistance. To explain the early findings of Monzó et al [12], which were not reproduced by other authors, including the present study, Kelley et al [24] suggested that the primers used by Monzó et al [12] did not allow to discriminate TUBB from its pseudogenes [24]. Furthermore, the first studies reporting TUBB gene mutations were made in hamster cells [11] and in ovarian cancer cell lines [10] after selection by paclitaxel exposure, something that makes difficult a direct extrapolation of these findings to human tumours.

We have also evaluated the MSI status of the 34 ovarian carcinomas with quasimonomorphic BAT 26 and BAT 34 markers, but did not find any microsatellite unstable tumours. Some authors have described an association between cisplatin resistance and MMR system anomalies in ovarian adenocarcinomas [28-30], as well as in colon cancer cell lines [31-33]. Additionally, other studies found MSI in ovarian cancer, namely, in serous and clear cell histological types [34-40]. However, the frequency of MSI identified in those studies was quite low (0–14.3%), which is in agreement with our findings. To completely rule out any relationship between deficient mismatch repair and cisplatin resistance, one would have to analyse more microsatellite markers in a larger series of tumours paired with normal DNA.

Conclusion

We conclude that, contrarily to earlier suggestions, TUBB exon 4 mutations and MMR defects are not major mechanisms underlying paclitaxel and/or cisplatin resistance in ovarian cancer. Further investigation on alternative mechanisms of resistance to these drugs is warranted. Possible mechanisms to paclitaxel resistance are P-glycoprotein overexpression [5,41], differential β-tubulin isotype expression [5,42,43], and apoptosis deregulation [5,44-46]. Decrease in intracellular cisplatin level, increase of tolerance or repair of DNA lesions, and alterations in the apoptotic cascade have also been related with cisplatin resistance [5,47]. These studies are necessary to predict individual response of patients to these chemotherapeutic agents.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

BM carried out the molecular genetic studies and drafted the manuscript. IV participated in the design of the study and coordination. DP was responsible for clinical surveillance. AS was responsible for paraffin slides. IMP was responsible for the histopathologic analysis. CP carried out sequence alignment. MT coordinated the study. SC conceived the study and participated in its design and coordination.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/5/101/prepub

Acknowledgements

We thank the Portuguese Health Ministry for the financial support (Project nr. 191/99). B. Mesquita was a fellow of Fundação para Ciência e Tecnologia. We thank Mariano Monzó and collaborators for useful discussions during this work.

References

  • Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: the global picture. Eur J Cancer. 2001;37:S4–66. doi: 10.1016/S0959-8049(01)00267-2. [PubMed] [Cross Ref]
  • Crown J, O'Leary M. The taxanes: an update. Lancet. 2000;355:1176–1178. doi: 10.1016/S0140-6736(00)02074-2. [PubMed] [Cross Ref]
  • Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuert G, Kaye S, Vargote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three year results. J Natl Cancer Inst. 2000;92:699–708. doi: 10.1093/jnci/92.9.699. [PubMed] [Cross Ref]
  • McGuire , Ozols RF. Chemotherapy in advanced ovarian cancer. Semin Oncol. 1998;25:340–348. [PubMed]
  • Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3:502–516. doi: 10.1038/nrc1123. [PubMed] [Cross Ref]
  • Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 2000;88:2619–2628. doi: 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J. [PubMed] [Cross Ref]
  • Floyd-Smith GA, de Martinville B, Francke U. An expressed tubulin gene, TUBB, is located on the short arm of human chromosome 6 and two related sequences are dispersed on chromosome 8 and 13. Exp Cell Res. 1986;163:539–548. doi: 10.1016/0014-4827(86)90084-4. [PubMed] [Cross Ref]
  • Ludueña RF. Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol. 1998;178:207–275. [PubMed]
  • Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer. 1998;34:1535–1542. doi: 10.1016/S0959-8049(98)00227-5. [PubMed] [Cross Ref]
  • Giannakakou P, Sackett DL, Kang YK, Zhan Z, Butters JT, Fojo T, Poruchynsky MS. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem. 1997;272:17118–17125. doi: 10.1074/jbc.272.27.17118. [PubMed] [Cross Ref]
  • Gonzalez-Garay ML, Chang L, Blade K, Menick DR, Cabral F. A β-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J Biol Chem. 1999;271:23875–23882. doi: 10.1074/jbc.274.34.23875. [PubMed] [Cross Ref]
  • Monzó M, Rosell R, Sanchéz JJ, Lee JS, O'Brate A, Gonzalez-Larriba JL, Alberola V, Lorenzo JC, Nunez L, Ro JY, Martin C. Paclitaxel resistance in non-small cell lung cancer associated with β-tubulin gene mutations. J Clin Oncol. 1999;17:1786–1793. [PubMed]
  • de las Alas MM, Aebi S, Fink D, Howell SB, Los G. Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst. 1997;89:1537–1541. doi: 10.1093/jnci/89.20.1537. [PubMed] [Cross Ref]
  • Vaurs C, Bignon YJ. Quoi de neuf sur la signification des instabilités microssatellitaires dans les pathologies tumorales humaines? Bull Cancer. 1997;84:1061–1071. [PubMed]
  • Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res. 1998;4:1–6. [PubMed]
  • Lage H, Dietel M. Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J Cancer Res Clin Oncol. 1999;125:156–165. doi: 10.1007/s004320050258. [PubMed] [Cross Ref]
  • Soignet SL, Spriggs DR. General principles of chemotherapy. In: Barakat RR, Bevers MW, Gershenson DM, editor. Handbook of Gynecologic Oncology. London: Martin Dunitz; 2001. pp. 243–263.
  • Hoang JM, Cottu PH, Thuille B, Salmon RJ, Thomas G, Hamelin R. BAT – 26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res. 1997;57:300–303. [PubMed]
  • Zhou XP, Hoang JM, Li YJ, Seruca R, Carneiro F, Sobrinho-Simoes M, Lothe RA, Gleeson CM, Russel SE, Muzeau F, Flejou JF, Hoang-Xuan L, Lidereau R, Thomas G, Hamelin R. Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer. 1998;21:101–107. doi: 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4. [PubMed] [Cross Ref]
  • Lamb P, Crawford L. Characterization of the human P53 gene. Mol Cell Biol. 1986;6:1379–1385. [PMC free article] [PubMed]
  • Benedet JL, Bender H, Jones H, III, Ngan HYS, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70:209–262. doi: 10.1016/S0020-7292(00)90001-8. [PubMed] [Cross Ref]
  • Sale S, Sung R, Shen P, Yu K, Wang Y, Duran GE, Kim JH, Fojo T, Oefner PJ, Sikic BI. Conservation of the class I β-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol Cancer Ther. 2002;1:215–225. [PubMed]
  • Lamendola DE, Duan Z, Penson RT, Oliva E, Seiden MV. Beta tubulin mutations are rare in ovarian carcinoma. Anticancer Res. 2003;23:681–686. [PubMed]
  • Kelley MJ, Li S, Harpole DH. Genetic analysis of the β-tubulin gene, TUBB, in non-small-cell lung cancer. J Nat Cancer Inst. 2001;93:1886–1888. doi: 10.1093/jnci/93.24.1886. [PubMed] [Cross Ref]
  • Hasegawa S, Miyoshi Y, Egawa C, Ishitobi M, Tamaki Y, Monden M, Nogushi S. Mutational analysis of the class I beta-tubulin gene in human breast cancer. Int J Cancer. 2002;101:46–51. doi: 10.1002/ijc.10575. [PubMed] [Cross Ref]
  • Maeno K, Ito K, Hama Y, Shingu K, Kimura M, Sano M, Nakagomi H, Tsuchiaya S, Fujimori M. Mutation of the class I β-tubulin gene does not predict response to paclitaxel for breast cancer. Cancer Lett. 2003;198:89–97. doi: 10.1016/S0304-3835(03)00279-9. [PubMed] [Cross Ref]
  • Urano N, Fujiwara Y, Hasegawa S, Miyoshi Y, Nogushi S, Takiguchi S, Yasuda T, Yano M, Monden M. Absence of beta-tubulin gene mutation in gastric carcinoma. Gastric Cancer. 2003;6:108–112. [PubMed]
  • Orth K, Hung J, Gazdar A, Bowcock A, Mathis JM, Sambrook J. Genetic instability in human ovarian cancer cell lines. Proc Natl Acad Sci USA. 1994;91:9495–9499. [PMC free article] [PubMed]
  • Aebi S, Haidar BK, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996;56:3087–3090. [PubMed]
  • Fink D, Nebel S, Norris PS, Baergen RN, Wilczynski SP, Costa MJ, Haas M, Cannistra SA, Howell SB. Enrichment for DNA mismatch repair deficient cells during treatment with cisplatin. Int J Cancer. 1998;77:741–746. doi: 10.1002/(SICI)1097-0215(19980831)77:5<741::AID-IJC13>3.0.CO;2-4. [PubMed] [Cross Ref]
  • Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nheme A, Christen RD, Howell SB. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996;56:4881–4886. [PubMed]
  • Aebi S, Fink D, Gordon R, Kim HK, Zheng H, Finj JL, Howell SB. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res. 1997;3:1763–1767. [PubMed]
  • Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehme A, Christen RD, Haas M, MacLeod CL, Howell SB. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 1997;57:1841–1845. [PubMed]
  • Fujita M, Enomoto T, Yoshino K, Nomura T, Buzard GS, Inoue M, Okudaira Y. Microsatellite instability and alterations in the hMSH2 gene in human ovarian cancer. Int J Cancer. 1995;64:361–366. [PubMed]
  • Pieretti M, Cavalieri C, Conway PS, Gallion HH, Powell DE, Turker MS. Genetic alterations distinguish different types of ovarian tumors. Int J Cancer. 1995;64:434–440. [PubMed]
  • Arzimanoglou II, Lallas T, Osborne M, Barber H, Gilbert F. Microsatellite instability differences between familial and sporadic ovarian cancers. Carcinogenesis. 1996;17:1799–1804. [PubMed]
  • Haas CJ, Diebold J, Hirschmann A, Rohrbach H, Schid S, Lohrs U. Microsatellite analysis in serous tumors of the ovary. Int J Gynecol Pathol. 1999;18:158–162. [PubMed]
  • Geisler JP, Goodheatr MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA, Buller RE. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer. 2003;98:2199–2206. doi: 10.1002/cncr.11770. [PubMed] [Cross Ref]
  • Cai KQ, Albarracin C, Rosen D, Zhong R, Zheng W, Luthra R, Broaddus R, Liu J. Microsatellite instability and alteration of the expression of the hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol. 2004;35:552–559. doi: 10.1016/j.humpath.2003.12.009. [PubMed] [Cross Ref]
  • Singer G, Kallinowski T, Hartmann A, Dietmaier W, Wild PJ, Schraml P, Sauter G. Different types of microsatellite instability in ovarian carcinoma. Int J Cancer. 2004;112:643–646. doi: 10.1002/ijc.20455. [PubMed] [Cross Ref]
  • Parekh H, Wiesen K, Simpkins H. Acquisition of taxol resistance via P-glycoprotein and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem Pharmacol. 1997;53:461–470. doi: 10.1016/S0006-2952(97)83383-7. [PubMed] [Cross Ref]
  • Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR. Altered β-tubulin isotype expression in paclitaxel resistant human prostate carcinoma cells. Brit J Cancer. 1998;77:562–566. [PMC free article] [PubMed]
  • Kavallaris M, Burkhart CA, Horowitz SB. Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol. Brit J Cancer. 1999;80:1020–1025. doi: 10.1038/sj.bjc.6690507. [PMC free article] [PubMed] [Cross Ref]
  • Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res. 1997;57:229–233. [PubMed]
  • Liu JR, Fletcher B, Page C, Hu C, Nunez G, Baker V. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol Oncol. 1998;70:398–403. doi: 10.1006/gyno.1998.5125. [PubMed] [Cross Ref]
  • Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SH. BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol. 1998;16:2583–2590. [PubMed]
  • Perego P, Romanelli S, Carenini N, Magnani I, Leone R, Bonetti A, Paolicchi A, Zunino F. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to taxol. Ann Oncol. 1998;9:423–430. doi: 10.1023/A:1008265012435. [PubMed] [Cross Ref]

Articles from BMC Cancer are provided here courtesy of BioMed Central

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...